Read by QxMD icon Read


Sandeep Verma, Ruchi Singh, Vanila Sharma, Ram Avtar Bumb, Narendra Singh Negi, V Ramesh, Poonam Salotra
BACKGROUND: Leishmaniasis is a spectrum of diseases with great relevance to public health. Conventional diagnostic methods are time consuming, needing trained personnel. A robust, rapid and cost effective diagnostic test is warranted for on-time diagnosis and field application. METHODS: We have developed a loop mediated isothermal amplification (LAMP) assay with primers (nā€‰=ā€‰6) based on Leishmania donovani kDNA for detection of Leishmania infection, using a closed tube to prevent cross-contamination...
March 23, 2017: BMC Infectious Diseases
Santanu Biswas, Abhishek Subramanian, Ibrahim M ELMojtaba, Joydev Chattopadhyay, Ram Rup Sarkar
Visceral leishmaniasis (VL) is a deadly neglected tropical disease that poses a serious problem in various countries all over the world. Implementation of various intervention strategies fail in controlling the spread of this disease due to issues of parasite drug resistance and resistance of sandfly vectors to insecticide sprays. Due to this, policy makers need to develop novel strategies or resort to a combination of multiple intervention strategies to control the spread of the disease. To address this issue, we propose an extensive SIR-type model for anthroponotic visceral leishmaniasis transmission with seasonal fluctuations modeled in the form of periodic sandfly biting rate...
2017: PloS One
Pabitra Saha, Swagata Ganguly, Moytrey Chatterjee, Soumendu Bikash Das, Pratip K Kundu, Subhasish K Guha, Tamal K Ghosh, Dilip K Bera, Nandita Basu, Ardhendu K Maji
Asymptomatic leishmaniasis may drive the epidemic and an important challenge to reach the goal of joint Visceral Leishmaniasis (VL) elimination initiative taken by three Asian countries. The role of these asymptomatic carriers in disease transmission, prognosis at individual level and rate of transformation to symptomatic VL/Post Kala-azar Dermal Leishmaniasis (PKDL) needs to be evaluated. Asymptomatic cases were diagnosed by active mass survey in eight tribal villages by detecting antileishmanial antibody using rK39 based rapid diagnostic kits and followed up for three years to observe the pattern of sero-conversion and disease transformation...
February 2017: PLoS Neglected Tropical Diseases
Gomathy Sethuraman, Neetu Bhari, Poonam Salotra, Venkatesh Ramesh
Postkala-azar dermal leishmaniasis (PKDL) is a complication of kala-azar or visceral leishmaniasis and is caused by Leishmania donovani. We describe an Indian male patient with the rarer erythrodermic form of PKDL and multiple unusual skin lesions viz. verrucous, annular and mucosal ulceration.
January 27, 2017: BMJ Case Reports
Robert Kimutai, Ahmed M Musa, Simon Njoroge, Raymond Omollo, Fabiana Alves, Asrat Hailu, Eltahir A G Khalil, Ermias Diro, Peninah Soipei, Brima Musa, Khalid Salman, Koert Ritmeijer, Francois Chappuis, Juma Rashid, Rezika Mohammed, Asfaw Jameneh, Eyasu Makonnen, Joseph Olobo, Lawrence Okello, Patrick Sagaki, Nathalie Strub, Sally Ellis, Jorge Alvar, Manica Balasegaram, Emilie Alirol, Monique Wasunna
INTRODUCTION: In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous first-line VL treatment in the region. To monitor the new treatment's safety and effectiveness in routine clinical practice a pharmacovigilance (PV) programme was developed. METHODS: A prospective PV cohort was developed...
March 2017: Clinical Drug Investigation
Vidya Nand Ravi Das, Ravindra Nath Pandey, Niyamat Ali Siddiqui, Lloyd A C Chapman, Vijay Kumar, Krishna Pandey, Greg Matlashewski, Pradeep Das
BACKGROUND: Visceral Leishmaniasis (VL) is a neglected tropical disease that afflicts some of the poorest populations in the world including people living in the Bihar state of India. Due to efforts from local governments, NGOs and international organizations, the number of VL cases has declined in recent years. Despite this progress, the reservoir for transmission remains to be clearly defined since it is unknown what role post kala-azar dermal leishmaniasis (PKDL) and asymptomatic infections play in transmission...
December 2016: PLoS Neglected Tropical Diseases
Mohammed Ahmed A Ahmed, Ahmed A Ahmed, Saeed M Omar, Gamal K Adam, Tajeldin M Abdallah, AbdelAziem A Ali
BACKGROUND: Since 1900s, visceral leishmaniasis (VL) has been among the most important health problems in Sudan, particularly in the endemic areas such as eastern and central regions. METHODS: This was a cross sectional, hospital-based study conducted from 1(st) January 2015 to 31(st) December 2015 to investigate the epidemiological factors of VL in Gadarif hospital, eastern Sudan. RESULTS: During the study period there were 47 identified children with VL among 145 suspected cases...
December 7, 2016: BMC Public Health
Wei Zhang, Peihua Chen, Lianqun Zhou, Zhen Qin, Keqiang Gao, Jia Yao, Chuanyu Li, Ping Wang
The perception of sour taste in mammals is important for its basic modality properties and avoiding toxic substances. We explore a biomimetic bioelectronic tongue, which integrate MEA (microelectrode array) and taste receptor cell for acid detection as a switch. However, the acid-sensing mechanism and coding of the taste receptor cells in the periphery is not well understood, with long-standing debate. Therefore, we firstly construct a Hodgkin-Huxley type mathematical model of whole-cell acid-sensing taste receptor cells based on the electrophysiologic patch clamp recordings with different acid sensitive receptor expressing and different acidic stimulations...
June 15, 2017: Biosensors & Bioelectronics
Sushmita Das, Rakesh Mandal, Vidya Nand Rabidas, Neena Verma, Krishna Pandey, Ashok Kumar Ghosh, Sreekant Kesari, Ashish Kumar, Bidyut Purkait, Chandra Sekhar Lal, Pradeep Das
BACKGROUND: Visceral leishmaniasis (VL), with the squeal of Post-kala-azar dermal leishmaniasis (PKDL), is a global threat for health. Studies have shown sodium stibogluconate (SSG) resistance in VL patients with chronic arsenic exposure. Here, we assessed the association between arsenic exposure and risk of developing PKDL in treated VL patients. METHODS: In this retrospective study, PKDL patients (n = 139), earlier treated with SSG or any other drug during VL, were selected from the study cohort...
October 2016: PLoS Neglected Tropical Diseases
Sarfaraz Ahmad Ejazi, Pradyot Bhattacharya, Md Asjad Karim Bakhteyar, Aquil Ahmad Mumtaz, Krishna Pandey, Vidya Nand Ravi Das, Pradeep Das, Mehebubar Rahaman, Rama Prosad Goswami, Nahid Ali
BACKGROUND: Visceral Leishmaniasis (VL), a severe parasitic disease, could be fatal if diagnosis and treatment is delayed. Post kala-azar dermal leishmaniasis (PKDL), a skin related outcome, is a potential reservoir for the spread of VL. Diagnostic tests available for VL such as tissue aspiration are invasive and painful although they are capable of evaluating the treatment response. Serological tests although less invasive than tissue aspiration are incompetent to assess cure. Parasitological examination of slit-skin smear along with the clinical symptoms is routinely used for diagnosis of PKDL...
October 2016: PLoS Neglected Tropical Diseases
Golam Hasnain, Mohammad Sohel Shomik, Prakash Ghosh, Mamun Or Rashid, Shakhawat Hossain, Shinjiro Hamano, Dinesh Mondal
Post-kala-azar dermal leishmaniasis (PKDL) without previous visceral leishmaniasis (VL) is a rare dermatological manifestation of Leishmania infection. To date, most of the reported cases neither showed parasitological confirmation nor explained the outcome of treatment. Herein, we report three confirmed cases that were were successfully cured after miltefosine treatment.
December 7, 2016: American Journal of Tropical Medicine and Hygiene
Supriya Khanra, Nibedeeta Rani Sarraf, Shantanabha Das, Anjan Kumar Das, Syamal Roy, Madhumita Manna
Visceral Leishmaniasis or Kala-azar is caused by the protozoan parasites belonging to the Genus Leishmania. Once thought eradicated from the Indian subcontinent, the disease came back with drug resistance to almost all prevalent drugs. Molecular epidemiological studies revealed the polymorphic nature of the population of the main player of the disease, Leishmania donovani and involvement of other species (L. tropica) and other genus (Leptomonas) with the disease. This makes control measures almost futile. It also strongly demands the characterization of each and every isolate mandatory which is not done...
December 2016: Acta Tropica
Kumar Avishek, Himanshu Kaushal, Sreenivas Gannavaram, Ranadhir Dey, Angamuthu Selvapandiyan, V Ramesh, Narender Singh Negi, Uma S Dubey, Hira L Nakhasi, Poonam Salotra
Currently no effective vaccine is available for human visceral leishmaniasis(VL) caused by Leishmania donovani. Previously, we showed that centrin1 and p27gene deleted live attenuated Leishmania parasites (LdCen1(-/-) and Ldp27(-/-)) are safe, immunogenic and protective in animal models. Here, to assess the correlates of protection, we evaluated immune responses induced by LdCen1(-/-) and Ldp27(-/-) in human blood samples obtained from healthy, healed VL (HVL), post kala-azar dermal leishmaniasis(PKDL) and VL subjects...
2016: Scientific Reports
Eduard E Zijlstra
Post-kala-azar dermal leishmaniasis (PKDL) is a common complication of visceral leishmaniasis (VL) caused by Leishmania donovani. Because of its possible role in transmission it is considered a public health problem in VL endemic areas. The clinical features include a skin rash consisting of macules, papules or nodules in an otherwise healthy individual; this presentation is determined by the immune response towards parasites in the skin that probably persisted from the previous VL episode. The immune response in VL, cured VL and PKDL is the result of changes in the cytokine profile that only in part can be captured under the Th1 and Th2 dichotomy...
2016: Parasites & Vectors
Waleed Al-Salem, Jennifer R Herricks, Peter J Hotez
BACKGROUND: Visceral leishmaniasis (VL), caused predominantly by Leishmania donovani and transmitted by both Phlebotomus orientalis and Phlebotomus martini, is highly endemic in East Africa where approximately 30 thousands VL cases are reported annually. The largest numbers of cases are found in Sudan - where Phlebotomus orientalis proliferate in Acacia forests especially on Sudan's eastern border with Ethiopia, followed by South Sudan, Ethiopia, Somalia, Kenya and Uganda. Long-standing civil war and unrest is a dominant determinant of VL in East African countries...
2016: Parasites & Vectors
Siddhivinayak Hirve, Marleen Boelaert, Greg Matlashewski, Dinesh Mondal, Byron Arana, Axel Kroeger, Piero Olliaro
BACKGROUND: As Bangladesh, India and Nepal progress towards visceral leishmaniasis (VL) elimination, it is important to understand the role of asymptomatic Leishmania infection (ALI), VL treatment relapse and post kala-azar dermal leishmaniasis (PKDL) in transmission. METHODOLOGY/ PRINCIPAL FINDING: We reviewed evidence systematically on ALI, relapse and PKDL. We searched multiple databases to include studies on burden, risk factors, biomarkers, natural history, and infectiveness of ALI, PKDL and relapse...
August 2016: PLoS Neglected Tropical Diseases
Muzamil Yaqub Want, Priya Yadav, Farhat Afrin
Visceral leishmaniasis (VL) or kala-azar is a vector borne infectious disease caused by the protozoan parasites of the genus Leishmania. VL is endemic in more than 85 countries with an estimated 0.2-0.5 million people at risk, causing high morbidity and mortality across the globe. In the absence of effective vaccines, treatment solely relies on chemotherapy and can be 100% fatal within two years, if left untreated. However, the present chemotherapeutics is limited by toxicity, non-compliance, location of parasites within the lysosomal vacuoles of macrophages, impairing the accession of many potential antileishmanial drugs, prolonged and cumbersome regimen that is unaffordable by rural population with alarming increase in unresponsiveness, complications of post kala-azar dermal leishmaniasis (PKDL) and HIV co-infections...
March 2016: Journal of Nanoscience and Nanotechnology
Ehud Inbar, Philip Lawyer, David Sacks, Daniele Podini
BACKGROUND: In the Indian sub-continent, visceral leishmaniasis (VL), also known as kala azar, is a fatal form of leishmaniasis caused by the kinetoplastid parasite Leishmania donovani and transmitted by the sand fly Phlebotomus argentipes. VL is prevalent in northeast India where it is believed to have an exclusive anthroponotic transmission cycle. There are four distinct cohorts of L. donovani exposed individuals who can potentially serve as infection reservoirs: patients with active disease, cured VL cases, patients with post kala azar dermal leishmaniasis (PKDL), and asymptomatic individuals...
May 2016: PLoS Neglected Tropical Diseases
D Mondal, M G Hasnain, M S Hossain, D Ghosh, P Ghosh, H Hossain, J Baker, R Nath, R Haque, G Matlashewski, S Hamano
INTRODUCTION: Post-kala-azar dermal leishmaniasis (PKDL) is a dermatological complication that occurs primarily among treated visceral leishmaniasis (VL) patients, and sporadically in a few without a history of VL. It mostly affects children and adolescents but is also common in adults. The conventional treatment with 120 intramuscular injections of sodium stibogluconate (SSG) is phasing out. Miltefosine (MF) is the only eventual alternative to SSG; however, its efficacy and safety profiles for treatment of children and adolescents with PKDL are lacking...
May 17, 2016: BMJ Open
Vijayamahantesh, Ajay Amit, Manas R Dikhit, Raj K Pandey, Kuljit Singh, Ritesh Mishra, V N R Das, Pradeep Das, Sanjiva Bimal
Serum adenosine deaminase (ADA) activity increases in diseases where cellular immunity is involved. Since cell-mediated immune responses play a paramount role in the pathogenesis and healing of the visceral leishmaniasis, therefore, the present study was undertaken to evaluate the serum ADA activity in different pathological conditions. Adenosine deaminase was determined in sera of active visceral leishmaniasis (VL) patients (n = 39), active postkala-azar dermal leishmaniasis (PKDL) cases (n = 34) at the point of diagnosis and after treatment stages along with healthy controls (n = 30), endemic healthy subjects (n = 34) and endemic asymptomatic subjects (n = 34)...
2016: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"